Publication Topic

Thompson CM. The useful chemistry of perfluorinated compounds: Managing safety. The sticky subject of non-stick: Regulatory science challenges of per- and poly-fluorinated compounds (PFAS). Texas A&M University Interdisciplinary Faculty of Toxicology Training Program, 2019 Annual Regulatory Science Symposium, College Station, TX, August 2019.

Proctor D. Use of the latest science in cancer risk assessment for hexavalent chromium: Is it time to step away from the default regulatory approaches? Invited presentation to the International Union of Toxicology (IUTOX) / International Congress of Toxicology (ICT) Meeting, Honolulu, HI, June 2019.

Choksi NY, Truax J, Layton A, Matheson J, Mattie D, Varney T, et al. 2019. United States regulatory requirements for skin and eye irritation testing. Cutan Ocul Toxicol 38(2):141–155; doi: 10.1080/15569527.2018.1540494. PMID: 30418044.

Mihalchik-Burhans AL, Sullivan DW. 2019. Bridging issues of route. In: Gad S (ed), Integrated Safety and Risk Assessment for Medical Devices and Combination Products, pp. 273–297. Springer.

Casey WM, Chang X, Allen DG, Ceger PC, Choksi NY, Hsieh JH, et al. 2018. Evaluation and optimization of pharmacokinetic models for in vitro to in vivo extrapolation of estrogenic activity for environmental chemicals. Environ Health Perspect 126(9):97001; doi: 10.1289/EHP1655. PMID: 30192161.

Wikoff D. Moving beyond theory to the use of systematic review to support regulatory decision making for evidence-based risk assessment. Society of Toxicology 57th Annual Meeting, San Antonio, TX, March 2018.

Proctor DM. Updating the regulatory risk assessment for hexavalent chromium in California: Implications for regulatory standards. Association of Environmental Health Sciences San Diego, CA, March 2018.

Clippinger A, Allen D, Jarabek AM, Corvaro M, Gaça M, Gehen S, Hotchkiss JA, Patlewicz G, et al. 2018. Alternative approaches for acute inhalation toxicity testing to address global regulatory and non-regulatory data requirements: An international workshop report. Toxicol In Vitro 48(April):53-70; doi: 10.1016/j.tiv.2017.12.011. PMID: 29277654.

Klaren WD, Grimm FA, Shen H, Rusyn I. In vitro approaches to grouping of complex substances and UVCBs: A case study of olefin streams. Abstract 3325, Society of Toxicology 57th Annual Meeting, San Antonio, TX, 2018.

Drechsel DA, Barlow CA, Bare JL, Jacobs NF, Henshaw JL. 2018. Historical evolution of regulatory standards for occupational and consumer exposures to industrial talc. Regul Toxicol Pharmacol 92(Feb):251–267; doi: 10.1016/j.yrtph.2017.12.005. PMID: 29233769.

Butler L, Guzzie-Peck P, Hartke J, Bogdanffy M, Will Y, Diaz D, Mortimer-Cassen E,.., Greene N, et al. Revised draft EMA guidance on early clinical trials: Potential impacts and industry response. Abstract P204, American College of Toxicology 38th Annual Meeting. Int J Toxicol 37(1):75-76; doi: 10.1177/10915818177494. Palm Springs, CA, November 2017.

Vincent MJ, Bernstein JA, Basketter D, LaKind JS, Dotson GS, Maier A. 2017. Chemical-induced asthma and the role of clinical, toxicological, exposure and epidemiological research in regulatory and hazard characterization approaches. Regul Toxicol Pharmacol 90(Nov):126–132; doi: 10.1016/j.yrtph.2017.08.018. PMID: 28866265.

Renner G, Audebert F, Burfeindt J, Calvet B, Caratas-Perifan M, Leal ME, Gorni R, Long A, et al. 2017. Cosmetics Europe guidelines on the management of undesirable effects and reporting of serious undesirable effects from cosmetics in the European Union. Cosmetics 4(1):1; doi: 10.3390/cosmetics4010001.

Reddick H. An introduction to regulatory toxicology. Science Teachers and Industry Workshop, Kilgore, TX, 2015.

Eaker DW. Impact of changes to the FDA biocompatibility guidance: An industry perspective. Invited Speaker, MedCon 2014, FDA and Xavier Health, Cincinnati, OH, May 2014.

Eaker DW. Global regulatory harmonization efforts for review and approvals of combination medical devices. Invited Speaker, ANTEC 2014, Society of Plastics Engineers, Las Vegas, NV, April 2014.

Juberg DR, Borghoff SJ, Becker RA, Casey W, Hartung T, Holsapple MP, Marty MS, Mihaich EM, et al. 2014. t4 Workshop report — Lessons learned, challenges, and opportunities: The U.S. Endocrine Disruptor Screening Program. Altex 31(1):63-78 doi: 10.14573/altex.1309171. PMID: 24114257.

Sahmel J, Cowan DM, Panko JM, Paustenbach DJ. 2012. Future trends in risk management: Control banding and REACH. Chapter 19 in: Perkins J, Gray C. (eds). Modern Industrial Hygiene, Volume III: Control of Chemical Agents, Part IV: Risk Management. ACGIH, Cincinnati, OH, pp. 727–764.

Panko JM, Kreider ML, Ferrara J. REACH – A review of the regulation and technical components of registration. AIHA Pittsburgh Section, Pittsburgh, PA, February, 2010.

Williams ES, Panko JM, Paustenbach DJ. 2009. The European Union’s REACH Regulation: A review of its history and requirements. Crit Rev Toxicol 39(7):553–575; doi: 10.1080/10408440903036056. PMID: 19650717.